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at-risk was set to 0.72, and it was assumed that new dialysis
modality distribution would reach by year 3. The model
allowed various sensitivity analyses. RESULTS: If PD utilization
increased to 25% without any reimbursement increase for PD,
5-year savings was estimated to be €13 million. If APD was
reimbursed by an additional €1300 per patient, 5-year savings
increased to €18 million, assuming overall PD utilization
increased to 30% and APD share of PD increased from 4.5% to
30%. If APD reimbursement increased an additional €2300 per
patient and APD share of PD increased to 50%, it would
require 35% of all PD patients undergoing dialysis treatment to
achieve €18 million savings. Finally, at this level of additional
APD reimbursement, 5-year savings increase to €25 million as
PD utilization increases to 40%. With €25 million in savings, an
additional 1478 patient-years of treatment could be provided in
Romania. CONCLUSION: With additional reimbursement for
PD and the resulting increase in PD utilization, there is an
opportunity for government to lower the total dialysis budget.
Government can apply the savings to treat additional ESRD
patients.
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OBJECTIVES: There is expected to be an increase in the number
of patients needing dialysis in the UK over the next 5 years.
Outcomes for the different modalities available, haemodialysis
(HD) and peritoneal dialysis (PD), have been shown to be similar
yet the majority of dialysis patients are treated with HD. Any
changes in dialysis delivery that could lead to a more efﬁcient use
of resources could increase the number of RRT patients that
could be treated. The objective of this evaluation is to project a
ﬁve-year impact on total dialysis costs when there is a hypoth-
esised shift in modality from HD to PD. METHODS: An Excel-
based budget impact model was used to estimate the impact of a
shift in modality utilisation. The model takes into account dialy-
sis modality shares, annual average cost of treating patients per
modality, annual RRT growth rate and years to reach new
modality distribution. Cost data from a recent UK study were
used. At baseline (June 2007) there were 23,133 RRT patients
undergoing dialysis therapy, 79% using HD and 21% using PD.
Annual direct cost per patient was £39,412 for HD, £20,764
for home HD (HHD), £22,350 for automated PD (APD), and
£16,355 for continuous ambulatory PD (CAPD). Total costs
included drug treatment and transport costs. At baseline, 2% of
the HD population was on HHD and 48% of the PD population
was on CAPD. RESULTS: If PD utilisation increases to 30% (of
which 60% is APD) by 2011, the cumulative 5-year budget is
reduced by a total of £166 million. This cumulative 5-year
savings can provide an additional 5,036 patient-years of treat-
ment. CONCLUSIONS: In the UK, an increased use of PD
provides an opportunity to treat additional patients within a
ﬁxed budget, which is a potential solution to the increased
demand for RRT in the coming years.
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OBJECTIVES: Identiﬁcation of the better drug for immunosup-
pression following renal transplantation. METHODS: Efﬁcacy
data sources included completed comparative randomized clini-
cal trials of Sandimmun Neoral and cyclosporine A generics
(Stolyarevich E. S. 2006, Taber D. J. et al. 2005, CTS 2001); costs
were derived from the wholesale prices of the study drugs
(Protek, Cia International, Shreya Corporation, as of 11 October
2006). The study evaluated the costs of initial and maintenance
immunosuppression, treatment of rejection episodes, and hemo-
dialysis necessitated by transplant death in the compared groups.
RESULTS: Analysis of randomized clinical trials has revealed
that Sandimmun Neoral is superior to cyclosporine A generics as
regards one-year renal graft survival rates (88% vs. 78%) (CTS
2001). Furthermore, application of cyclosporine A generics
entails more frequent episodes of acute rejection (25% vs. 39%),
recurrent rejection (4% vs. 13%), and rejection requiring admin-
istration of antibodies (8% vs. 19%, Taber D. J. et al. 2005). The
total cost of 2-year therapy was over 58.8 million roubles and 72
million roubles per 100 patients in the Sandimmun Neoral and
cyclosporine A generics groups, respectively. CONCLUSION:
Sandimmun Neoral is the leading alternative for immuno-
suppression following renal transplantation, i.e. it is preferable
from a clinicoeconomic perspective.
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OBJECTIVES: Identiﬁcation of the better drug for immunosup-
pression following renal transplantation. METHODS: Efﬁcacy
data sources included completed comparative randomized clini-
cal trials of cyclosporine microemulsion (Sandimmun Neoral,
CsA) and tacrolimus (Prograf, Tac). Costs were derived from the
wholesale prices of the study drugs (international drug distribu-
tor Shreya, as of 25 September 2006). Costs of other medicines
with the exception of calcineurin inhibitors (Mycophenolate
Mofetil, corticosteroids, Azathioprine), transplantation surgery,
diagnostic laboratory procedures, and pharmacokinetic monitor-
ing of blood concentrations of drugs were considered constant
and left out of calculations in this comparative study. RESULTS:
Analysis of randomized clinical trials has revealed similar efﬁca-
cies for both analyzed treatment options, whereas the safety
proﬁle of tacrolimus is more of a problem: the frequency rates of
the new onset post-transplant diabetes mellitus for CsA and Tac
are 26.5% and 33.6%, respectively, according to Vincenti F.
(2005), or 9.8% and 15.4%, respectively, as reported by Keown
P. (2004). The rates of diarrhea in the study of Levy G. (2005)
were 14% in the CsA group and 29% in those treated with Tac.
This study evaluated the costs of initial and maintenance immu-
nosuppression with Sandimmun Neoral and Prograf, which were
approximately 22,600 roubles vs. 58,700 roubles for initial
therapy and 176,300 roubles vs. 952,300 roubles for one-year
maintenance immunosuppression, respectively. The amount of
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